0001108205-24-000049.txt : 20240523
0001108205-24-000049.hdr.sgml : 20240523
20240523160822
ACCESSION NUMBER: 0001108205-24-000049
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240521
FILED AS OF DATE: 20240523
DATE AS OF CHANGE: 20240523
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hohneker John
CENTRAL INDEX KEY: 0001695378
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30347
FILM NUMBER: 24978236
MAIL ADDRESS:
STREET 1: C/O DIMENSION THERAPEUTICS, INC.
STREET 2: 840 MEMORIAL DRIVE 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CURIS INC
CENTRAL INDEX KEY: 0001108205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 043505116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING C, SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-503-6500
MAIL ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING C, SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
wk-form4_1716494885.xml
FORM 4
X0508
4
2024-05-21
0
0001108205
CURIS INC
CRIS
0001695378
Hohneker John
128 SPRING STREET
BUILDING C - SUITE 500
LEXINGTON
MA
02421
1
0
0
0
0
Non Qualified Stock Option
11.62
2024-05-21
4
A
0
4250
11.62
A
2034-01-19
Common Stock
4250
4250
D
This option grant, as disclosed in Curis Inc.'s 2024 proxy statement, was approved by the Board of Directors of Curis, Inc. on January 20, 2024, contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the Fifth Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 21, 2024, at the 2024 annual meeting of shareholders, Curis's shareholders approved the Fifth Amended and Restated 2010 Plan.
The option grant described in this Form 4 filing vests as to 100% of the underlying shares on January 20, 2025.
/s/ Diantha Duvall, Attorney-in-fact
2024-05-23